Cordioli G, Mazzocco C, Schepers E, Brugnolo E, Majzoub Z
Department of Periodontology, Institute of Clinical Dentistry, University of Padova, Padova; Private Practice, Padova, Italy.
Clin Oral Implants Res. 2001 Jun;12(3):270-8. doi: 10.1034/j.1600-0501.2001.012003270.x.
This clinical study was undertaken to: 1) evaluate the use of bioactive glass Biogran combined with autogenous bone as grafting material for maxillary sinus augmentation with simultaneous implant placement using radiography and histology; and 2) document the short-term post-loading success of implants inserted in sinus cavities augmented with this material. Unilateral or bilateral sinus augmentation was performed in 12 patients with 3-5 mm of alveolar crestal bone height in the posterior maxilla prior to grafting. The sinuses were grafted with bioactive glass mixed in a 4:1 ratio with autogenous bone. Simultaneously, 2-3 threaded titanium implants were inserted into the augmented sinuses. Second stage surgery was carried out 9 to 12 months post implantation. At abutment connection, 10 core biopsy specimens were taken from different grafted sites and evaluated histologically. All 27 implants were clinically stable at second stage surgery. A mean increase in mineralized tissue height of 7.1 +/- 1.6 mm was evident when comparing the pre-surgical CT scans with those performed 9-12 months following the sinus augmentation procedure. Evaluation of the cores yielded a mean of 30.6 +/- 5.7% of bone tissue in the grafted sites. One implant failed during the prosthetic phase while the remaining 26 implants were stable 12 months post loading. This study suggests that Biogran/autogenous bone graft combination used in one-stage sinus augmentation yields sufficient quality and volume of mineralized tissue for predictable simultaneous implant placement in patients with 3-5 mm of bone height prior to grafting.
1)使用影像学和组织学方法,评估生物活性玻璃Biogran与自体骨联合作为上颌窦提升同期种植的移植材料的应用情况;2)记录使用该材料进行上颌窦提升后植入种植体的短期加载后成功率。在12例上颌后牙区牙槽嵴顶骨高度为3 - 5mm的患者中,于植骨前进行单侧或双侧上颌窦提升。将生物活性玻璃与自体骨按4:1的比例混合后植入上颌窦。同时,将2 - 3枚螺纹钛种植体植入上颌窦提升部位。植入后9至12个月进行二期手术。在连接基台时,从不同的植骨部位采集10份核心活检标本并进行组织学评估。在二期手术时,所有27枚种植体临床稳定。将术前CT扫描与上颌窦提升术后9 - 12个月的CT扫描进行比较,矿化组织高度平均增加了7.1 +/- 1.6mm。对核心标本的评估显示,植骨部位骨组织平均占比为30.6 +/- 5.7%。在修复阶段有1枚种植体失败,其余26枚种植体在加载后12个月保持稳定。本研究表明,在一期上颌窦提升中使用Biogran/自体骨移植组合可为术前骨高度为3 - 5mm的患者同时进行种植提供足够质量和体积的矿化组织,以实现可预测的种植效果。